Drug Profile
Polynitroxylated pegylated haemoglobin - SynZyme Technologies
Alternative Names: HemoZyme; nanoRBC; PEG-haemoglobin - SynZyme; SanFlowLatest Information Update: 28 Sep 2020
Price :
$50
*
At a glance
- Originator SynZyme Technologies
- Class Haemoglobins; Polyethylene glycols
- Mechanism of Action Nitric oxide donors; Oxygen carriers
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity No
- Available For Licensing Yes
Highest Development Phases
- No development reported Brain injuries
Most Recent Events
- 28 Sep 2020 No recent reports of development identified for preclinical development in Brain injuries in USA (Parenteral)
- 02 Aug 2016 Polynitroxylated pegylated haemoglobin - SynZyme is available for licensing -http://www.synzyme.com/gallery.html
- 02 Aug 2016 Preclinical trials in Brain injuries in USA (Parenteral)